FGH BioTech, Inc., a drug discovery and development company, specializes in the development of drugs for the treatment of metabolic disorders. Products are used to treat obesity, non-alcoholic fatty liver disease, type II diabetes and lipid disorders non-alcoholic fatty liver disease, cardiovascular disease, and cancer therapy. . Obesity and related disorders currently account for almost 20% of the total healthcare budget. Anchored in technology licensed from Baylor College of Medicine, the lead development candidate (FGH11019) is currently in late stage preclinical development for obesity. The firm has developed FGH 10019, a small molecule that provides the ability to manipulate the master metabolic switch regulating homeostasis between lipid synthesis and lipid oxidation using a mechanism consistent with normal physiology; and blocks activation of sterol regulatory element-binding proteins.
